<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587444</url>
  </required_header>
  <id_info>
    <org_study_id>330-01</org_study_id>
    <secondary_id>3300100</secondary_id>
    <secondary_id>CR4023159908</secondary_id>
    <nct_id>NCT00587444</nct_id>
  </id_info>
  <brief_title>Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass</brief_title>
  <acronym>Heparin Dosing</acronym>
  <official_title>Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study has been completed and is in the data analysis and manuscript writing phase of the
      project.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure blood loss</measure>
    <time_frame>within 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>transfusion requirements</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Postoperative Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control standard dose heparin dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose heparin dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hepcon guided therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>300u/kg of heparin for CPB ACT performed. If ACT is &lt; 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is&gt;480 seconds</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HH or high heparin</intervention_name>
    <description>initial dose of 450u/kg for CPB ACT performed additional bolus given if result is &lt;600 seconds anytime during CPB</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin concentration HC</intervention_name>
    <description>will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.
All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and non-pregnant female patients scheduled for elective cardiac surgery
             requiring CPB will be eligible for enrollment.

        Exclusion Criteria:

          -  Age less than 18 or greater than 90 years; emergency surgery

          -  Circulatory arrest

          -  Combined non-cardiac procedures such as carotid endarterectomy

          -  Congenital heart repair

          -  Off-CPB coronary artery bypass grafting (CABG)

          -  Clotting disorder

          -  Fibrinolytic agents (e.g. streptokinase), severe hepatic disease

          -  Aprotinin use

          -  Cooling &lt; 28 degrees C during CPB

          -  Dialysis dependent renal failure; and

          -  Platelet receptor GP3a/2b antagonists medication received within 48 hours of surgery.
             Patients that are not receiving tranexamic acid (TA) intraoperatively will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Oliver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>October 14, 2009</last_update_submitted>
  <last_update_submitted_qc>October 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. William Oliver</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>heparin management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

